Tranzyme Pharma To Report First Quarter 2013 Financial Results

RESEARCH TRIANGLE PARK, N.C., May 2, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the Company will report first quarter 2013 financial results after the close of the market on Thursday, May 9, 2013.

About Tranzyme Pharma

Tranzyme Pharma is a biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics. All of Tranzyme's drug discovery activities are based on its proprietary small molecule macrocyclic template chemistry (MATCH™) technology, which has also been successfully used to generate drug candidates in partnership with other pharmaceutical companies. MATCH enables the rapid construct of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner. By leveraging MATCH, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical need and continues to pursue funded drug discovery partnerships. Additional information on Tranzyme can be found at www.tranzyme.com .
CONTACT: Inquiries:         Susan Sharpe         Director, Corporate Communications         (919) 328-1109         ssharpe@tranzyme.com

If you liked this article you might like

3 Health Care Stocks Under $10 to Watch

3 Health Care Stocks Under $10 to Watch

Tranzyme Stomach Paralysis Drug Comes Up Short

Tranzyme Stomach Paralysis Drug Comes Up Short

5 Stocks Under $10 Poised to Move Higher

5 Stocks Under $10 Poised to Move Higher

Insiders Trading TZYM, ALKS, CAKE

Insiders Trading TZYM, ALKS, CAKE

For Biotech, 'Fail' is Making a Big Comeback

For Biotech, 'Fail' is Making a Big Comeback